We are live on ! Find out more
ADVM

Adverum Biotechnologies
ADVM

Delisted

ADVM was delisted on the 8th of December, 2025.

Back to rankings

78 hedge funds and large institutions have $55.6M invested in Adverum Biotechnologies in 2022 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 11 increasing their positions, 29 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

12,800% more call options, than puts

Call options by funds: $1.29M | Put options by funds: $10K

1% more funds holding

Funds holding: 77 → 78 (+1)

7% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 15

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% less ownership

Funds ownership: 5.9% → 5.89% (-0%)

21% less capital invested

Capital invested by funds: $70M → $55.6M (-$14.4M)

62% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 29

Holders
78
Holders Change
+1
Holders Change %
+1.3%
% of All Funds
1.34%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
16
Increased
11
Reduced
29
Closed
15
Calls
$1.29M
Puts
$10K
Net Calls
+$1.28M
Net Calls Change
-$607K

Top Buyers

Rank Fund Capital Flow
1
SCM
Soleus Capital Management
Connecticut
+$7.34M
2
ACM
AIGH Capital Management
Maryland
+$1.58M
3
AC
Antara Capital
New York
+$1.41M
4
Marshall Wace
Marshall Wace
United Kingdom
+$665K
5
CCM
CAAS Capital Management
New York
+$177K

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$3.6M
2
RCM
RA Capital Management
Massachusetts
-$2.07M
3
EC
EcoR1 Capital
California
-$1.26M
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$595K
5
JP Morgan Chase
JP Morgan Chase
New York
-$548K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
76
RA Capital Management
Massachusetts
– -$2.07M -172,602 Closed
EC
77
EcoR1 Capital
California
– -$1.26M -104,670 Closed
AG
78
Algert Global
California
– -$140K -11,669 Closed
Susquehanna International Group
79
Susquehanna International Group
Pennsylvania
– -$125K -9,489 Closed
Rafferty Asset Management
80
Rafferty Asset Management
New York
– -$84K -6,995 Closed
CM
81
Crestline Management
Texas
– -$78K -6,485 Closed
JMPWA
82
JP Morgan Private Wealth Advisors
California
– -$19K -1,617 Closed
SG
83
StoneX Group
New York
– -$17.8K -1,483 Closed
MWP
84
Madison Wealth Partners
Wisconsin
– -$17K -1,441 Closed
YIH
85
Y-Intercept (HK)
Hong Kong
– -$14K -1,130 Closed
B
86
Brightworth
Georgia
– -$12K -1,000 Closed
Federated Hermes
87
Federated Hermes
Pennsylvania
– -$6K -490 Closed
New York State Common Retirement Fund
88
New York State Common Retirement Fund
New York
– -$1K -73 Closed
CAPTRUST Financial Advisors
89
CAPTRUST Financial Advisors
North Carolina
– -$1K -50 Closed
1 2 3
4

ADVM Hedge Fund Activity: Q3 2022 in Review

78 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q3 2022, worth a combined $55.6M — down 21% from $70M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new ADVM positions and 15 closed out — a net gain of 1 holder — while 11 added to existing stakes and 29 trimmed.

The largest buyer was Soleus Capital Management, opening a new position worth an estimated $7.34M. The largest seller was Artal Group, exiting entirely with an estimated $3.6M sold.

  • 78 institutional investors held Adverum Biotechnologies (ADVM) as of Q3 2022, up from 77 in Q2 2022.
  • Funds reported $55.6M of Adverum Biotechnologies stock for Q3 2022, down 21% quarter-over-quarter.
  • 16 funds opened new Adverum Biotechnologies positions in Q3 2022 and 15 closed out, a net change of +1 holder.
  • The largest Adverum Biotechnologies buyer in Q3 2022 was Soleus Capital Management, an estimated $7.34M added.
  • The largest Adverum Biotechnologies seller in Q3 2022 was Artal Group, an estimated $3.6M sold.

Based on aggregated 13F filings for Q3 2022.